Norwegian company invests in Denmark's Port of Kalundborg  

Norwegian pharmaceutical company Pronova BioPharma has broken ground for a new DKK 1.5 bn factory in the Port of Kalundborg
Norwegian pharmaceutical company Pronova BioPharma (previously Pronova Biocare) has broken ground for a new DKK 1.5 bn (USD 281 m) factory in the Port of Kalundborg on Zealand, the island on which the Danish capital Copenhagen stands. The factory will produce pharmaceutical products featuring a high concentration of omega-3 fatty acids derived from fish oil for the treatment of cardiac and circulatory diseases. The oil is obtained from fish found in South America, and is shipped to Europe for processing.
The new facility at the Port of Kalundborg will consist of a factory as well as administration premises and storage tanks. Pronova BioPharma chose the Port of Kalundborg in preference to 30 other European locations that the company also considered. The new facility will create 200 jobs for the locality.
Pronova BioPharma has its headquarters in Lysaker, Norway and its primary production plant in Sandefjord, Norway. In H1 2002 Pronova BioPharma generated revenues of NOK 487.4 m (USD 87.5 m). Pronova BioPharma is currently owned by Ferd Private Equity Fund I.
The Port of Kalundborg is one of Denmark's largest ports with annual goods turnover in excess of 3.5 million tons. The port covers more than 800,000 m2, and is located only 9 nautical miles from the T-route, the deep water route to the Baltic region. The news was reported by Erhvervsbladet.
Link > Pronova BioPharma  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×